Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023)

Alto Neuroscience has reported Other Non-Current Liabilities over the past 1 years, most recently at $1.4 million for Q4 2023.

  • Quarterly results put Other Non-Current Liabilities at $1.4 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $1.4 million (changed N/A YoY), and the annual figure for FY2023 was $1.4 million, changed.
  • Other Non-Current Liabilities reached $1.4 million in Q4 2023 per ANRO's latest filing, down from $1.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q1 2023 and bottomed at $1.4 million in Q4 2023.